ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD46 Antibody-drug Conjugate FOR46

Also written as “FOR46” and “FG-3246”.

Its studies are mostly in Prostatic Neoplasms · Multiple Myeloma, led by 2 companies.

Drug pageAnti-CD46 Antibody-drug Conjugate FOR46: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jun 20, 20183 company-led studies, 1 open or runningNext primary completion: Mar 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fortis Therapeutics20 open or runningphase 1since Jun 20, 2018Jun 20, 2018none ahead
Kyntra Bioits history only11 open or runningphase 2since Feb 19, 2025Feb 19, 2025Mar 31, 2028phase 2 · NCT06842498

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Fortis Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 20, 2018First study: phase 1 study in Prostate Cancer MetastaticFirst studyNCT03575819 · 56 enrolled · United States
  2. Aug 21, 2018Phase 1 study in Multiple MyelomaNCT03650491 · 31 enrolled · United States

TargetBeta

CD46 →read by rule
“An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cluster of differentiation 46 (CD46; membrane cofactor protein; MCP) and ”NCIt, by rule

Studies

All 2 Fortis Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03650491Multiple Myeloma · United States1CompletedJan 31, 202231
NCT03575819Prostate Cancer Metastatic · United States1CompletedNov 16, 202356

How it is read

Names in the registry

  • “FOR46”, 2 entries
  • “FG-3246”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.